Medtronic
MDTWhat is it worth to you? Move six assumptions and see what value per share you get, and where you stand against the price and other users.
At $100.72 (close on November 18) and with the other assumptions at their starting point, Medtronic's sales would need to grow 10.3% a year for ten years; over its last decade, the median was 3.3%. Value it with your own assumptions.
Its accounts, year by year
| Year end | Sales | Growth | Margin |
|---|---|---|---|
| 04/2016 | 28,833 | — | 19.9% |
| 04/2017 | 29,710 | 3.0% | 19.3% |
| 04/2018 | 29,953 | 0.8% | 23.3% |
| 04/2019 | 30,557 | 2.0% | 21.5% |
| 04/2020 | 28,913 | −5.4% | 17.6% |
| 04/2021 | 30,117 | 4.2% | 16.0% |
| 04/2022 | 31,686 | 5.2% | 19.3% |
| 04/2023 | 31,227 | −1.4% | 18.7% |
| 04/2024 | 32,364 | 3.6% | 17.1% |
| 04/2025 | 33,537 | 3.6% | 19.0% |
| 04/2026 | 36,364 | 8.4% | 19.0% |
Sales in millions of dollars. The margin is the operating margin before stock pay, as a percentage of sales. Each row is a fiscal year, by the month it ends. Source: the reports Medtronic files with the SEC, the US securities regulator; the latest is for the fiscal year ended April 24, 2026. See the report.
The model's starting point
- Sales growth, years 1 to 10: 3.6% a year.
- Sales growth after year 10: 2.5% a year.
- Operating margin, before stock pay: 19.0% of sales.
- Working capital needed to grow: $14.4 per $100 of new sales.
- Capital spending: 4.9% of sales.
- Stock pay to employees: 1.4% of sales.
- Discount rate, the same for every company: 10%.
These are the six assumptions the page starts with; each user moves them as they see fit.
Reference points
They come from its accounts and its share price, compared with the median of the companies on grinboss. They are not a recommendation.
For
- Its share price moves less than the market: a five-year beta of 0.49; the median is 0.94.
- It is one of the big ones: it sells $36.4 billion a year; the median of grinboss companies is $15.1 billion.
- Its margin changes little from one year to the next: 1.9 points on average, and 4.0 at most; the median is 2.8 points.
- Over ten years, its worst fall from a high was 49%; the median is 56%.
Against
- It ties up $14 in inventory and unpaid customer bills for every $100 of new sales, more than the median ($2).
- Its sales grew only 2.3% a year on average over 10 years, from $28.8 billion to $36.4 billion; the median of grinboss companies is 6.6%.
- Its margin has fallen over these years, from 20% to 19%.
- Its capital spending takes 4.9% of its sales every year, more than the median (3.3%).
Next results: November 24, 2026.
Other companies in its sector (Health Care)
Merck & Co. (MRK) · Moderna (MRNA) · Mettler Toledo (MTD) · Pfizer (PFE) · Insulet Corporation (PODD) · Regeneron Pharmaceuticals (REGN) · ResMed (RMD) · Revvity (RVTY) · All companies
Loading the model…